[Recombinant interferon alfa in the treatment of essential thrombocythemia].
Essential thrombocythaemia, a clonal myeloproliferative disease characterized by a persisting increase of the number of thrombocytes, their abnormal morphology and function, is a special clinical and therapeutic problem which calls for a comprehensive approach. Based on a group of their own patients and on data from the literature, the authors discuss the asset of interferon alpha in the treatment of essential thrombocythaemia.
Tóthová
E
E
Oddelenie klinickej hematológie FNsP, Kosice.
Fricová
M
M
Mudronová
B
B
Stecová
N
N
Svorcová
E
E
Kafková
A
A
Guman
T
T
D000328:Adult; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D013922:Thrombocytosis / Q000628:therapy*
D007370:Interferon Type I; D011994:Recombinant Proteins